These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19090985)

  • 1. The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.
    Borders AS; de Almeida L; Van Eldik LJ; Watterson DM
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S12. PubMed ID: 19090985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ).
    Bachstetter AD; Xing B; de Almeida L; Dimayuga ER; Watterson DM; Van Eldik LJ
    J Neuroinflammation; 2011 Jul; 8():79. PubMed ID: 21733175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
    Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
    Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p38α mitogen-activated protein kinase is a key regulator of myelination and remyelination in the CNS.
    Chung SH; Biswas S; Selvaraj V; Liu XB; Sohn J; Jiang P; Chen C; Chmilewsky F; Marzban H; Horiuchi M; Pleasure DE; Deng W
    Cell Death Dis; 2015 May; 6(5):e1748. PubMed ID: 25950478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism.
    Bachstetter AD; Xing B; Van Eldik LJ
    J Neuroinflammation; 2014 Oct; 11():175. PubMed ID: 25297465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
    Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM
    J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors.
    Madkour MM; Anbar HS; El-Gamal MI
    Eur J Med Chem; 2021 Mar; 213():113216. PubMed ID: 33524689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target.
    Kaminska B; Gozdz A; Zawadzka M; Ellert-Miklaszewska A; Lipko M
    Anat Rec (Hoboken); 2009 Dec; 292(12):1902-13. PubMed ID: 19943344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The localization and function of p38α mitogen-activated protein kinase in rat oocytes.
    Hu S; Yu Q; Wang Y; Ke D; Zhou F; Cheng G; Xia W; Zhu C
    Reprod Domest Anim; 2018 Jun; 53(3):636-643. PubMed ID: 29430805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway.
    Meng F; Yamagiwa Y; Taffetani S; Han J; Patel T
    Am J Physiol Cell Physiol; 2005 Oct; 289(4):C971-81. PubMed ID: 15917303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy.
    Yuasa K; Okubo K; Yoda M; Otsu K; Ishii Y; Nakamura M; Itoh Y; Horiuchi K
    Sci Rep; 2018 Jun; 8(1):9037. PubMed ID: 29899565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).
    Fischer S; Koeberle SC; Laufer SA
    Expert Opin Ther Pat; 2011 Dec; 21(12):1843-66. PubMed ID: 22082194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of naphthyl-N-acylhydrazone p38α MAPK inhibitors with in vivo anti-inflammatory and anti-TNF-α activity.
    Freitas RHCN; Cordeiro NM; Carvalho PR; Alves MA; Guedes IA; Valerio TS; Dardenne LE; Lima LM; Barreiro EJ; Fernandes PD; Fraga CAM
    Chem Biol Drug Des; 2018 Feb; 91(2):391-397. PubMed ID: 28815968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Angle on MK2 Inhibition-Optimization and Evaluation of Prevention of Activation Inhibitors.
    Hedström U; Norberg M; Evertsson E; Lever SR; Munck Af Rosenschöld M; Lönn H; Bold P; Käck H; Berntsson P; Vinblad J; Liu J; Welinder A; Karlsson J; Snijder A; Pardali K; Andersson U; Davis AM; Mogemark M
    ChemMedChem; 2019 Oct; 14(19):1701-1709. PubMed ID: 31325352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.
    González-Medina M; Miljković F; Haase GS; Drueckes P; Trappe J; Laufer S; Bajorath J
    Eur J Med Chem; 2020 Feb; 187():112004. PubMed ID: 31881458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Map kinase signaling as therapeutic target for neurodegeneration.
    Ahmed T; Zulfiqar A; Arguelles S; Rasekhian M; Nabavi SF; Silva AS; Nabavi SM
    Pharmacol Res; 2020 Oct; 160():105090. PubMed ID: 32707231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Novel Inhibitory Allosteric Site in p38α.
    Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
    PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.